Beyond drug price: A comparison of overall costs of anti‐vascular endothelial growth factor therapy alternatives for neovascular age‐related macular degeneration in Norway

Documenti analoghi

• Transition to high‐dose aflibercept and intraocular pressure risk: A two‐step approach to injection volume at Oslo University Hospital
  di: Øystein Kalsnes Jørstad, et al.
  Pubblicazione: (2025)
• Injection burden and treatment intervals of aflibercept in observe‐and‐plan regimen for neovascular age‐related macular degeneration
  di: Yousif Subhi, et al.
  Pubblicazione: (2024)
• Comparative efficacy of intravitreal anti‐VEGF therapy for neovascular age‐related macular degeneration: A systematic review with network meta‐analysis
  di: Emilie T. S. Butler, et al.
  Pubblicazione: (2025)
• Impact of delayed appointments on treatment outcomes in neovascular macular degeneration
  di: Petri Purola, et al.
  Pubblicazione: (2026)
• Recurrence after treat‐and‐extend suspension in neovascular age‐related macular degeneration: A real‐world analysis by macular neovascularization subtype
  di: Geoffrey Zeender, et al.
  Pubblicazione: (2026)